Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...
Vielight Neuro RX Gamma device and irradiation configuration used in the randomized, double-blind, sham-controlled trial. The ...
MedPage Today on MSN
FDA Approves At-Home Device for Treatment-Resistant Depression
The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...
Research shows that vagus nerve stimulation can provide long-lasting benefits for patients who do not respond to conventional treatments Around 20% of adults in the United States will experience major ...
News-Medical.Net on MSN
Implanted vagus nerve stimulation device offers lasting relief for severe depression
About 20% of U.S. adults experience major depression in their lifetime. For most people, symptoms improve within a few ...
TIESA will use Open-LIFU in AI-guided, noninvasive research on neuromodulation for mental health conditions. SAN ...
About 20% of U.S. adults experience major depression in their lifetime. For most people, symptoms improve within a few ...
The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...
This approval represents a significant regulatory milestone, making Proliv™Rx the first and only at-home neuromodulation ...
Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...
Detailed price information for Nexalin Technology Inc (NXL-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback